Last reviewed · How we verify
Epinephrine 1/1000 — Competitive Intelligence Brief
phase 3
Catecholamine; adrenergic agonist
Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Emergency Medicine; Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Epinephrine 1/1000 (Epinephrine 1/1000) — Ministry of Health, Spain. Epinephrine is a catecholamine that activates alpha and beta adrenergic receptors to increase heart rate, blood pressure, and bronchial dilation.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Epinephrine 1/1000 TARGET | Epinephrine 1/1000 | Ministry of Health, Spain | phase 3 | Catecholamine; adrenergic agonist | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors | |
| Epinephrin 0.07 | Epinephrin 0.07 | Kasr El Aini Hospital | marketed | Catecholamine; adrenergic agonist | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors | |
| Atropine sulfate and epinephrine | Atropine sulfate and epinephrine | Dar El Oyoun Hospital | marketed | Anticholinergic agent and sympathomimetic amine combination | Muscarinic acetylcholine receptors (atropine); alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors (epinephrine) | |
| Racemic adrenaline | Racemic adrenaline | Oslo University Hospital | marketed | Sympathomimetic amine; adrenergic agonist | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors | |
| Epinephrine (Adrenaline) | Epinephrine (Adrenaline) | Aga Khan University | marketed | Catecholamine; adrenergic agonist | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors | |
| epinephrine perfusion | epinephrine perfusion | Central Hospital, Nancy, France | marketed | Sympathomimetic amine / Catecholamine | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors | |
| Ephedrine, bolus | Ephedrine, bolus | University of Parma | marketed | Sympathomimetic amine; adrenergic agonist | Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Catecholamine; adrenergic agonist class)
- Kasr El Aini Hospital · 2 drugs in this class
- Aga Khan University · 1 drug in this class
- Icahn School of Medicine at Mount Sinai · 1 drug in this class
- Ministry of Health, Spain · 1 drug in this class
- University of Louisville · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Epinephrine 1/1000 CI watch — RSS
- Epinephrine 1/1000 CI watch — Atom
- Epinephrine 1/1000 CI watch — JSON
- Epinephrine 1/1000 alone — RSS
- Whole Catecholamine; adrenergic agonist class — RSS
Cite this brief
Drug Landscape (2026). Epinephrine 1/1000 — Competitive Intelligence Brief. https://druglandscape.com/ci/epinephrine-1-1000. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing